About this trial
Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Funded by the French National Cancer Institute (INCa), UroCCR prospectively collects comprehensive real-world data on patient care and disease evolution, while systematically linking these records with annotated biological samples (plasma, urine, and both healthy and tumour tissues). For each case, more than one thousand variables may be recorded, covering clinical, imaging, and patient-reported information.
More than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels.
By combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patient with kidney cancer
Patient with no opposition to collection of its data for the study
Disqualifiers
None
Trial population
Patients with Kidney cancer
Trial design
Cohort
Prospective
Treatments tested in this trial
Radical nephrectomy versus partial nephrectomy (according surgeon judgement)
Procedure/Surgery
Treatment groups
Trial outcomes
Primary outcomes
Promotion of Prospective Research Projects
Development and conduct of prospective research projects across a broad range of thematic fields related to kidney cancer .
Secondary outcomes
Establishment of a Multicentre Annotated Biological Sample Collection
Annotation of biological samples collection and associated clinical data to support translational and clinical research in kidney cancer.
Advancement of Knowledge in Kidney Cancer Descriptive Epidemiology
Characterization of the incidence, prevalence, distribution, and trends of kidney cancer within the population
Advancement of Knowledge in Pharmacoepidemiology and Treatment Monitoring in Kidney Cancer
Evaluatation of treatment safety, efficacy, real-world indications, utilization patterns, and associated healthcare costs
Advancement of Knowledge in Quality of Life and Patient-Reported Outcomes in Kidney Cancer
Assessment of quality of life, patient-reported outcomes (PROs), and patient-reported experiences (PREs), including the personal, familial, professional, and social impact of kidney cancer. Data may be collected through digital tools such as UroConnect
Sponsors and contacts
Click on the lead sponsor to view all of their trials.